Newsroom
START’s Site Network Solidifies its Global Leadership in Urological Cancer Trials The START Center for Cancer Research (“START”), a global leader in early-phase oncology clinical trials, announces the expansion of its network with the acquisition of Carolina Urologic Research Center (“CURC”) the premier urologic clinical research site specializing in genitourinary
Expansion Brings New Principal Investigators, Expanded Site Resources, and Accelerated Trial Initiation to Support Breakthrough Blood Cancer Therapies 10 December 2024 The START Center for Cancer Research (“START”), the world’s largest community-based early phase cancer trial site network, has announced the expansion of its capabilities to support early phase hematological
28 October 2024 The START Center for Cancer Research (“START”), a global leader in early-phase cancer clinical trials, today announced a new strategic partnership with the Fundación Rioja Salud, a foundation dedicated to (i) the promotion and protection of health, (ii) the training, teaching, research, development and innovation of Health
START Dublin will offer patients with advanced cancer the opportunity to participate in cutting edge research and enhance the availability of new cancer drugs 14 October 2024 The Minister for Public Expenditure, NDP Delivery and Reform, Paschal Donohoe TD has today (Monday) officially opened START Dublin, the Republic of Ireland’s
San Antonio, TX – October 8, 2024. The START Center for Cancer Research (“START”) proudly announces that Amita Patnaik, MD, FRCPC, has been named to the prestigious PharmaVoice 100 list as a “Cancer Care Visionary.” This annual award celebrates inspiring individuals in life sciences who are making a profound impact
Dr. Takimoto to propel scientific and medical strategies and advance START’s leadership in global early-phase cancer research San Antonio, TX – October 2, 2024. The START Center for Cancer Research (“START”) proudly announces the appointment of Chris H. Takimoto, MD, PhD, FACP, as its new Chief Medical Officer. Dr. Takimoto,